Fonte: Proceedings. Nome do evento: International Conference of the Brazilian Association of Bioinformatics and Computational Biology/AB3C. Unidade: FCF
Assuntos: MODELAGEM MOLECULAR, DISLIPIDEMIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Glaucio Monteiro et al. Novel HMG-CoA reductase inhibitors development by integrating dyslipidemic patients genetic studies and molecular modelling. 2019, Anais.. Campos do Jordão: Associação Brasileira de Bioinformática e Biologia Computacional/AB3C, 2019. . Acesso em: 25 ago. 2024.APA
Ferreira, G. M., Oliveira, V. F. de, Kronenberger, T., Hirata, R. D. C., Hirata, M. H., & Feres, F. (2019). Novel HMG-CoA reductase inhibitors development by integrating dyslipidemic patients genetic studies and molecular modelling. In Proceedings. Campos do Jordão: Associação Brasileira de Bioinformática e Biologia Computacional/AB3C.NLM
Ferreira GM, Oliveira VF de, Kronenberger T, Hirata RDC, Hirata MH, Feres F. Novel HMG-CoA reductase inhibitors development by integrating dyslipidemic patients genetic studies and molecular modelling. Proceedings. 2019 ;[citado 2024 ago. 25 ]Vancouver
Ferreira GM, Oliveira VF de, Kronenberger T, Hirata RDC, Hirata MH, Feres F. Novel HMG-CoA reductase inhibitors development by integrating dyslipidemic patients genetic studies and molecular modelling. Proceedings. 2019 ;[citado 2024 ago. 25 ]